LM
Lincoln Medical Center at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
Lincoln Medical Center brings 5 presentations to IDWeek 2026 in Washington. Its program centres on real-world outcomes of anti-infective treatments. It covers bezlotoxumab for Clostridioides difficile infection, dalbavancin safety in high-risk patients, and tigecycline with or without a beta-lactam for complicated intra-abdominal infections.
| Organization | IDWeek 2026 Attendance |
|---|---|
LM Lincoln Medical Center Bronx, NY | |
Poster Thu Oct 22 12:15pm–1:30pm Bezlotoxumab and Short-Term Clinical Outcomes in Patients With Clostridioides difficile Infection: A Propensity-Matched Real-World Study Poster Thu Oct 22 12:15pm–1:30pm Chronic Hepatitis C and Incident Pulmonary Hypertension: A Multi-Center Propensity-Matched Cohort Study Poster Fri Oct 23 12:15pm–1:30pm Dalbavancin in High-Risk Patients: Real-World Safety with Zero 30-Day Mortality Poster Sat Oct 24 12:15pm–1:30pm Probiotic Use and Clinical Outcomes in Intra-abdominal Infections: A Propensity-Matched Real-World Cohort Study Poster Sat Oct 24 12:15pm–1:30pm Tigecycline Plus β-Lactam Versus Tigecycline Monotherapy in Complicated Intra-abdominal Infections: A Propensity-Matched Analysis |
Instantly find 20 buyers from Lincoln Medical Center
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction